AGMB

AgomAb Therapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

Belgium

Next Earnings Date

Business Summary

AgomAb Therapeutics operates as a clinical-stage biotechnology company developing therapeutics, monetizing value through the advancement of proprietary drug candidates rather than recurring product revenue. Cash generation in this model comes from capital raises, strategic partnerships, milestone payments, or eventual commercialization of approved therapies. The moat, when present, is intellectual property around novel biological pathways and the exclusivity granted by patents. Success depends less on scale and more on scientific differentiation, regulatory approval, and the ability to translate R&D spending into defensible, high-margin therapeutic assets.

 


Analyze AGMB on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$518

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

3

EV / EBITDA

-8

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

-

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.35

Next Year EPS Growth Estimate

-$1.87

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-38.70%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

-

Altman Z-Score

12.8

Return on Invested Capital (ROIC)

-38.30%

Current Ratio

14

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze AGMB on TradingView

Gainseekers Quantitative Analysis

Summary

At a $518M market cap, AGMB is being valued as a speculative biotech asset rather than an operating business. With no P/E or Forward P/E and EPS at -8, the company is firmly loss-making, and a -38.70% operating margin alongside -38.30% ROIC confirms capital is currently being destroyed, not compounded. However, the Altman Z-Score of 12.8 and a current ratio of 14 signal an exceptionally strong balance sheet and low near-term insolvency risk, which is critical in biotech. This is not a growth-at-a-reasonable-price story today; it is a balance-sheet-backed R&D option where survival odds look high but earnings visibility is effectively zero.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, AGMB operates in a sector increasingly shaped by AI-driven drug discovery and data analytics. The absence of profitability means technological leverage is essential to compress development timelines and improve capital efficiency. In biotech, competitive positioning often hinges on scientific platforms rather than legacy infrastructure, giving smaller players structural flexibility if they execute well.

The Bull Case

A value-oriented biotech investor could justify ownership purely on financial durability. A current ratio of 14 and an Altman Z-Score of 12.8 indicate substantial liquidity and minimal distress risk, which dramatically lowers the probability of dilutive emergency financing in the near term. While operating margin is -38.70% and ROIC is -38.30%, that capital burn appears supported by a fortified balance sheet rather than leverage, and the price-to-book of 3 suggests the market is not applying extreme speculative multiples. For investors comfortable underwriting clinical risk, the combination of strong solvency metrics and depressed earnings provides asymmetry: limited bankruptcy risk with upside tied to pipeline execution.

The Bear Case

The bear case is straightforward: this is a cash-burning biotech with EPS at -8, negative operating margins of -38.70%, and negative ROIC of -38.30%, meaning every dollar invested currently produces economic loss. There is no P/E, no Forward P/E, and no PEG Forward, which underscores a complete lack of earnings visibility and growth quantification. Sales Growth Next Year at -$1.87 and EPS Next Year estimated at -$1.35 indicate continued losses rather than inflection. With no dividend, zero yield, and no demonstrated profitability, shareholders are entirely dependent on future clinical success, making this a high-uncertainty equity despite its strong liquidity position.

Market Sentiment & Smart Money

Short Interest %

0.30%

Analyst Consensus

1.5

Average Analyst Price Target

$32.00

Institutional Ownership %

12.30%

1-Year Beta

1.71

Insider Buying % (6 Mo)

0.00%%

Distance to 52-Week High

60.40%

Distance to 52-Week Low

117.10%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.